Nanomaterial (NM) delivery to solid tumors has been the focus of intense research for over a
decade. Classically, scientists have tried to improve NM delivery by employing passive or …

Tumor-promoting inflammation and the avoidance of immune destruction are hallmarks of
cancer. While innate immune cells, such as neutrophils, monocytes, and macrophages, are …

Background Surufatinib showed superior efficacy in extrapancreatic neuroendocrine
tumours (NETs) in the phase 3 SANET-ep study. In SANET-p, we aimed to assess the …

At the centre of the therapeutic dilemma posed by cancer is the question of how to develop
more effective treatments that discriminate between normal and cancerous tissues. Decades …

Ovarian cancer (OC) remains a fatal malignancy because most patients experience
recurrent disease, which is resistant to chemotherapy. The outcomes for patients with …

Resistance to cancer therapy remains a major challenge in clinical oncology. Although the
initial treatment phase is often successful, eventual resistance, characterized by tumour …

Despite aggressive multimodal treatment, glioblastoma (GBM), a grade IV primary brain
tumor, still portends a poor prognosis with a median overall survival of 12–16 months. The …

Epithelial ovarian cancer (EOC) is among the top five causes of cancer-related death in
women, largely reflecting early, prediagnosis dissemination of malignant cells to the …

Tumor metastasis is an important reason for the difficulty of tumor treatment. Besides the
tumor cells themselves, the tumor microenvironment plays an important role in the process …

Tumour‐infiltrating immune cells regulate tumour development and progression either
negatively or positively. For example, cytotoxic lymphocytes (CTL) such as CD8+ T and …